<DOC>
	<DOCNO>NCT00127283</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Middle East , North America , Oceania , South America . The purpose study evaluate treatment Recombinant Factor VIIa ( eptacog alfa ( activate ) ) patient acute intracerebral bleeding . It expect patient recover without severe permanent disability acute treatment Recombinant Factor VIIa reduce intracerebral bleeding .</brief_summary>
	<brief_title>Recombinant Factor VIIa Acute Intracerebral Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Spontaneous intracranial hemorrhage ( ICH ) within 3 hour first symptom Patients secondary ICH Preexisting disability Haemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>